Shots:

• The P-III SOLO-1 Trial includes assessing of Lynparza (olaparib) (300mg bid) vs PBO in 391 patients in ratio (2:1) with newly-diagnosed- BRCA1/2 mutation who were in CR or PR following 1L Pt-based CT
• P-III SOLO-1 Trial results: reduction in risk of disease progression or death by 70%; PFS @ 36 mos. (60% vs 27%); mPFS for Lynparza didn’t reached 13.8 months as for PBO
• Lynparza (olaparib) is a novel PARPi- used in 20-000 patients worldwide and is approved for advanced OC and mBC. In July 2017- AZ & Merck globally collaborated to co-develop and co-commercialise Lynparza

 Ref: Astrazeneca | Image: Astrazeneca